Envelope protein 詳細
Molecule Name
Recombinant envelope protein
分子の別称
Envelope protein,Env polyprotein,Envelope glycoprotein,env
Drug Development Progress
治験薬の数6
市販薬剤の数1
研究＆開発段階Approved
ターゲットの別称
env，Submitted name: Recombinant envelope protein，Viral Envelope Proteins
バックグランド
The SARS-CoV-2 is composed of a double-layered lipid envelope, including Spike glycoprotein (S), Envelope protein (E), Membrane glycoprotein (M), and Nucleocapsid protein (Nucleocapsid protein, N). Among them, The amino acid sequence of the SARS-CoV-2 envelope protein is 95% identical of the SARS envelope protein.
Envelope protein 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Targeting HIV-1 Env gp140 antibodies | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | 詳細 | |
| Temelimab | GNN-001; GENHP-01; GNbAC-1 | Phase 2 Clinical | Geneuro Sa | Diabetes Mellitus, Type 1; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Post-Acute COVID-19 Syndrome | 詳細 |
| VIS-513 | VIS-513; Ab-513 | Phase 2 Clinical | Otsuka Pharmaceutical Co Ltd, Serum Institute Of India Ltd, Visterra Inc | Dengue | 詳細 |
| PGDM-1400 | PGDM-1400; PGDM1400LS | Phase 2 Clinical | International Aids Vaccine Initiative | Acquired Immunodeficiency Syndrome; HIV Infections; Sexually Transmitted Diseases, Viral | 詳細 |
| MGD-020 | MGD020 | Phase 1 Clinical | Macrogenics Inc | HIV Infections | 詳細 |
| GS-8588 | GS-8588 | Phase 1 Clinical | Gilead Sciences Inc | HIV Infections | 詳細 |
市販薬剤に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Tecovirimat | SIGA-246; ST-246 | Approved | Siga Technologies Inc | Tpoxx, Arestvyr | United States | Smallpox | Siga Technologies Inc | 2018-07-13 | Cowpox; Monkeypox; Orthopoxvirus Infection; Poxviridae Infections; Smallpox; Vaccinia | 詳細 |